“Translating genomic discovery to improve care for patients.”

Self-identified African-American patients who enroll in the ACCOuNT Translational project provide a blood sample which is sent to the Center for Personalized Therapeutics’ CLIA-certified laboratory for genotyping. Genotyping results and clinical decision support are made available within the Genomic Prescribing System (GPS).

Providers who staff inpatient services (physicians, pharmacists, nurse practitioners, and physician assistants) are eligible to enroll for the ACCOuNT Translational project and access patient genotyping results and pharmacogenomic recommendations via the GPS. Each hospital admission at which a preemptively genotyped patient is treated by an enrolled provider is evaluated. Data captured includes provider use of the GPS, as well medications prescribed or administered during the course of the admission. The primary outcome of interest is frequency of GPS use by study providers.

The ImPress Trial involves genotyping enrolled patients and delivering their genomic results through an online web portal integrated into the institutional electronic medical record. Providers in the pharmacogenomics arm will have access to this information during the patient’s surgical admission, allowing for tailored medication choices based on individual genetic profiles.

By tracking medication use and comparing the rate of high pharmacogenomic risk drugs between the two study arms, the primary outcome will provide valuable insights into the effectiveness of pharmacogenomics in guiding treatment decisions.

Chemotherapies such as fluoropyrimidinesand irinotecan have well-known pharmacogenomic associations, and preemptive pharmacogenomic testing prior to treatment offers the potential to identify patients at increased risk for toxicities. The implementation of Pharmacogenomic Testing in Oncology Care is a project whose goal is to provide personalized chemotherapy dosing in oncology patients, which we hypothesize will result in improved treatment tolerability as well as outcomes for cancer patients.

In PHOcUS Trial, oncologists can access the genetic makeup of each patient via genomic testing. With this valuable information, doctors can tailor chemotherapy unique to each patient, thus minimizing the adverse effects. Our “PHOcUS” is to take each patient’s genetics into account for optimized treatment outcomes.